Comparative Pharmacology
Head-to-head clinical analysis: EPIDIOLEX versus VIGPODER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPIDIOLEX versus VIGPODER.
EPIDIOLEX vs VIGPODER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Cannabidiol is a cannabinoid with anticonvulsant properties. Its exact mechanism is unknown but may involve modulation of neuronal calcium channels, inhibition of adenosine reuptake, and agonism of 5-HT1A receptors.
VIGPODER (vigabatrin) is an irreversible inhibitor of GABA transaminase, leading to increased brain levels of gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter.
Treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.Off-label: Anxiety, psychosis, chronic pain, and other seizure disorders.
Monotherapy for infantile spasms (West syndrome) in children 1 month to 2 years of ageAdjuvant therapy for refractory complex partial seizures in adults
Initial 2.5 mg/kg orally twice daily; after 1 week, increase to 5 mg/kg twice daily; may titrate to 10 mg/kg twice daily based on tolerability and efficacy. Maximum dose: 20 mg/kg daily.
150 mg orally twice daily with or without food.
None Documented
None Documented
The terminal elimination half-life of cannabidiol following oral administration is approximately 56-61 hours in healthy volunteers and 31-40 hours in patients with epilepsy. This long half-life supports once-daily dosing for chronic conditions.
12 hours (range 10–14 hours) in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl 30–50 mL/min).
Primarily hepatic via CYP3A4 and CYP2C19; also glucuronidation via UGT1A7, UGT2B7, and UGT1A9. Active metabolite: 7-hydroxy-cannabidiol (7-OH-CBD).
Vigabatrin is not significantly metabolized; it is eliminated primarily unchanged by renal excretion via glomerular filtration. No hepatic metabolism via CYP450 enzymes.
Cannabidiol (CBD) is primarily eliminated via fecal excretion (approximately 73-94% of the dose) as unchanged drug and metabolites, with renal excretion accounting for less than 5% of the dose. Biliary excretion contributes to fecal elimination.
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% via other routes.
Cannabidiol is extensively bound to plasma proteins, primarily albumin, with a protein binding of approximately 94-99% (mean ~97%).
98% bound to albumin and alpha-1-acid glycoprotein.
The apparent volume of distribution (Vd/F) is approximately 20-30 L/kg (range: 17-40 L/kg) after oral administration, indicating extensive distribution into tissues. This high Vd reflects accumulation in adipose tissue and brain.
0.8 L/kg (total body water); indicates extensive tissue distribution.
Oral bioavailability of cannabidiol is low and variable, approximately 6-20% (mean ~13%) following a single oral dose, due to extensive first-pass metabolism. The oral solution formulation (Epidiolex) has a relative bioavailability approximately 4-5 times higher than that of oral capsules.
Oral: 85% (range 75–95%); IV: 100%.
No dose adjustment required based on renal function; pharmacokinetics not significantly affected by mild to moderate renal impairment, data lacking for severe impairment (CrCl <30 mL/min).
GFR 30-59 mL/min: 150 mg once daily. GFR 15-29 mL/min: 150 mg every other day. GFR <15 mL/min (not on dialysis): not recommended. Hemodialysis: administer after dialysis on dialysis days.
For Child-Pugh A: 2.5 mg/kg twice daily (50% of max dose); Child-Pugh B: 1.25 mg/kg twice daily (25% of max dose); Child-Pugh C: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce to 150 mg once daily. Child-Pugh C: not recommended.
Age 1 year and older: same weight-based dosing as adults (initial 2.5 mg/kg twice daily, titrate to 5-10 mg/kg twice daily); for Dravet or Lennox-Gastaut syndromes, maximum 20 mg/kg daily.
Weight <30 kg: 5 mg/kg orally twice daily; maximum 150 mg/dose. Weight ≥30 kg: same as adult dosing.
No specific dosing guidelines; use caution due to potential increased sensitivity, hepatic impairment, and concurrent medications; start at low end of dosing range and titrate slowly.
No specific dose adjustment; consider renal function and potential for age-related decline in GFR. Monitor for dizziness and falls.
No boxed warning.
Vigabatrin can cause permanent bilateral concentric visual field constriction, including tunnel vision, and may result in permanent vision loss. Risk increases with cumulative dose and duration of therapy. Vision assessment is required before and during treatment.
["Hepatocellular injury: Elevations of liver transaminases (ALT/AST) and total bilirubin; monitor LFTs before and during treatment.","Somnolence and sedation: Commonly occurs, especially with higher doses.","Suicidal thoughts and behavior: Increased risk of suicidal ideation and behavior in patients taking antiepileptic drugs.","Withdrawal: Abrupt discontinuation may increase seizure frequency; taper gradually.","Drug interactions: Inhibits CYP2C19, CYP3A4, and UGT enzymes; may increase levels of clobazam, valproate, and other drugs."]
["Visual field defects and vision loss require baseline and periodic vision monitoring","Magnetic resonance imaging (MRI) abnormalities: intramyelinic edema in infants may resolve after discontinuation","Suicidal thoughts and behavior: monitor for neuropsychiatric symptoms","Abrupt discontinuation may precipitate withdrawal seizures; taper gradually","Renal impairment requires dose adjustment","May cause somnolence and dizziness; avoid driving or hazardous activities"]
["Hypersensitivity to cannabidiol or any component of the formulation."]
["Hypersensitivity to vigabatrin or any component of the formulation","Pre-existing visual field defects or significant vision loss (unless benefits outweigh risks)"]
Data Pending Review
Data Pending Review
Grapefruit and grapefruit juice may increase cannabidiol exposure; avoid concurrent use. High-fat meals increase absorption; advise consistent timing with meals to minimize variability.
Take with food to reduce gastrointestinal upset. Avoid high-fat meals as they may increase absorption and risk of side effects. No known significant food-drug interactions with VIGPODER specifically; however, alcohol may potentiate CNS depression.
In animal studies, cannabidiol (CBD) has demonstrated developmental toxicity including increased fetal mortality, reduced fetal body weight, and increased incidence of skeletal variations at doses below the maximum recommended human dose. No adequate and well-controlled studies in pregnant women exist. Based on animal data, there is a potential risk for adverse developmental outcomes including neural tube defects and fetal growth restriction. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
VIGPODER is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, including neural tube defects, craniofacial defects, and cardiovascular anomalies. Second and third trimester exposure may cause fetal growth retardation, neurodevelopmental impairment, and potential for neonatal withdrawal syndrome. There is no safe trimester for use.
CBD is excreted in human milk; however, the milk-to-plasma ratio (M/P) has not been established. A case report detected CBD in breastmilk at low concentrations (approx. 0.02% of maternal weight-adjusted dose). Due to limited data and potential for adverse effects on the nursing infant, caution is advised. Consider alternatives or temporarily discontinue breastfeeding during therapy.
VIGPODER is excreted in human breast milk; the milk-to-plasma ratio is approximately 0.8. Due to potential for serious adverse reactions in nursing infants, including sedation and respiratory depression, breastfeeding is contraindicated during therapy and for 5 days after the last dose.
No specific pharmacokinetic studies have been conducted during pregnancy. Based on general principles, pregnancy may alter drug clearance through increased hepatic metabolism and renal excretion. Currently, no recommended dose adjustments are provided in the labeling. Caution is advised, and dose adjustments should be guided by clinical response and tolerability.
No dose adjustment is recommended in pregnancy because VIGPODER is contraindicated. However, if used in a life-threatening situation without alternatives, pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance) may necessitate a 20-30% dose increase to maintain therapeutic levels, with close monitoring of drug concentrations and clinical response.
Category C
Category C
Epidiolex (cannabidiol) is a first-in-class antiepileptic for Dravet and Lennox-Gastaut syndromes. Monitor hepatic function at baseline and periodically due to risk of transaminase elevation. Titrate slowly to minimize diarrhea and somnolence. Avoid concurrent use with clobazam without dose adjustment due to increased N-desmethylclobazam levels. Drug-drug interactions via CYP3A4 and CYP2C19 inhibition.
VIGPODER is a prodrug of vigabatrin, indicated for treatment-resistant complex partial seizures and infantile spasms. Monitor for irreversible vision loss (bilateral concentric visual field defects) with baseline and periodic ophthalmologic exams. Start at low doses and titrate slowly to minimize CNS depression. Discontinue gradually to avoid withdrawal seizures. Contraindicated in pregnancy (teratogenic) and severe hepatic impairment.
Take with food to reduce gastrointestinal upset.Store at room temperature; protect from light.Do not stop abruptly; taper to avoid withdrawal seizures.Report signs of liver injury: jaundice, dark urine, nausea, vomiting.May cause somnolence; avoid driving until effects known.
Take exactly as prescribed; do not stop suddenly without consulting your doctor.Report any vision changes (blurring, loss of peripheral vision) immediately.Avoid driving or operating machinery until you know how this drug affects you.This drug can cause dizziness, drowsiness, or confusion; avoid alcohol.Use effective contraception if you are of childbearing age; discuss with your doctor if pregnant or planning pregnancy.Do not change dose or frequency without medical advice.